Acadia Pharmaceuticals (ACAD) PT Raised to $40 at Cantor Fitzgerald on KOL Support For Pimavanserin
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles Duncan raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $40.00 (from $30.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
